ArticleBMC complementary medicine and therapies2026
Comparative evaluation of the effects of Silymarin on the metastatic characteristics of MCF-7 and MDA-MB-231 breast cancer cells with two-dimensional and three-dimensional culture methods.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast cancer is one of the most common cancers among women worldwide, and metastasis plays an important role in its lethality. Silymarin (SLY) is a natural compound that has exhibited potential anticancer effects. However, its effects on the metastatic properties of different breast cancer cell lines remain unknown. Therefore, this study aimed to investigate the effects of SLY on the metastatic properties of two breast cancer cell lines (MCF-7 and MDA-MB-231) and evaluate differences between two-dimensional (2D) and three-dimensional (3D) cell culture models.
methodsThis study used 2D and 3D cell culture systems to evaluate the effects of SLY on cell proliferation, migration, and epithelial-mesenchymal transition (EMT). The effective dose of SLY was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assays in 2D and 3D cultures. In 2D cultures, wound healing assays, polymerase chain reaction (PCR) to evaluate mRNA levels and immunohistochemical analyses to evaluate protein expression. In 3D cultures, spheroids were formed, and Transwell migration assays, PCR for mRNA levels, and immunohistochemical analyses for protein expression were conducted.
resultsSLY effectively modulated proliferation, migration, and EMT in both cell lines. Notably, the 3D microenvironment exerted differential effects on drug sensitivity: MCF-7 cells showed increased sensitivity to SLY in 3D culture, whereas MDA-MB-231 cells exhibited increased resistance compared to 2D models.
conclusionsThese findings suggest that SLY exhibits promising antimetastatic potential in vitro, warranting further in vivo and clinical investigations to evaluate its efficacy as a supportive therapeutic candidate for breast cancer treatment. This study emphasizes the importance of 3D culture models for accurately evaluating the efficacy of anticancer drugs. Notably, SLY's effect on MMP-9 expression was found to be environment-dependent, showing a significant reduction specifically in the 3D spheroid model, which highlights its potential antimetastatic efficacy in more biomimetic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.